XELOX与XP化疗方案治疗胃癌术后复发转移患者的疗效及安全性比较

Comparison of efficacy and safety of XELOX and XP chemotherapy regimen in the treatment of patients with postoperative recurrence and metastasis of gastric cancer

目的比较XELOX与XP化疗方案治疗胃癌术后复发转移患者的疗效及安全性。方法选取2022年3月—2024年2月上饶市人民医院收治的120例胃癌术后复发转移患者作为研究对象,采用随机数字表法分为XELOX方案组和XP方案组,各60例。XELOX方案组采用XELOX化疗方案,XP方案组采用XP化疗方案。2组患者均以治疗21 d为1个疗程,连续治疗2个疗程。比较2组近期疗效,治疗前后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)及糖类抗原72-4(CA72-4)],不良反应。结果XELOX方案组与XP方案组客观缓解率、疾病控制率比较,差异均无统计学意义(20.00%vs.18.33%,χ2/P=0.054/0.817;63.33%vs.58.33%,χ2/P=0.315/0.575)。治疗2个疗程后,2组血清CEA、CA19-9及CA72-4水平均较治疗前降低,且XELOX方案组各指标水平低于XP方案组(P<0.05或P<0.01)。XELOX方案组Ⅲ~Ⅳ度胃肠道症状发生率低于XP方案组(P<0.05);2组Ⅰ~Ⅱ度胃肠道症状及Ⅰ~Ⅱ、Ⅲ~Ⅳ度血液/淋巴系统症状、手足综合征发生率比较,差异无统计学意义(P>0.05)。结论XELOX与XP化疗方案治疗胃癌术后复发转移患者的近期效果相当,但XELOX化疗方案更有利于降低患者肿瘤标志物水平,延缓病情进展,且安全性较高。

Objective To compare the clinical efficacy and safety of XELOX and XP chemotherapy regimen in the treatment of patients with postoperative recurrence and metastasis of gastric cancer.Methods A total of 120 patients with postoperative recurrence and metastasis of gastric cancer admitted to Shangrao People′s Hospital from March 2022 to February 2024,and they were divided into the XELOX regimen group and the XP regimen group,with 60 patients in each group.The XELOX regimen group was given XELOX chemotherapy regimen,and the XP regimen group was accepted XP chemotherapy regimen.Patients in the two groups were treated for 21 days as a course of treatment,and continuely treated for 2 courses.Recent curative effect,tumor markers(CEA,CA19-9,CA72-4)before and after treatment,and incidence of adverse reactions were compared between the two groups.Results There was no significant difference in the objective response rate or disease control rate between the XELOX regimen group and the XP regimen group(20.00%vs.18.33%,χ2/P=0.054/0.817;63.33%vs.58.33%,χ2/P=0.315/0.575).After 2 courses of treatment,serum levels of CEA,CA19-9,CA72-4 were lower than those before treatment,and the XELOX regimen group were lower than the XP regimen group(P<0.05 or P<0.01).Incidence of gastrointestinal symptom ofⅢ-Ⅳdegree of the XELOX regimen group was lower than that in the XP regimen group(P<0.05);There were no significant difference ofⅠ-Ⅱdegree gastrointestinal symptom,Ⅰ-Ⅱ,Ⅲ-Ⅳdegree blood/lymphatic system symptom and hand-foot syndrome between the two groups(P>0.05).Conclusion The short-term effect of XELOX chemotherapy regimen is similar to that of XP chemotherapy regimen in the treatment of patients with postoperative recurrence and metastasis of gastric cancer,but XELOX chemotherapy regimen is more conducive to reducing the level of tumor markers,delaying the progress of the disease,and with higher safety.